Loading...
Spinal cord injury (SCI) produces persistent neurologic deficits and has a poor prognosis in most patients. Incidence in the U.S. is high. Although physical therapy, cellular transplantation, and electrical stimulation have been examined as therapeutic approaches, pharmaceutical interventions to enhance neural repair are yet to be explored. The current manufacturer-sponsored study is probably the first report of an intrathecal medication designed to promote neural repair in humans with chronic cervical SCI. This experimental medication (AXER-204, a soluble Nogo-Receptor-Fc decoy) is not FDA-approved but has been fast-tracked.
The two-part, multicenter study evaluated safety, tolerability, and pharmacokinetics in adults (age range, 18–65) wit…